可让人头疼的是，很多患者在使用曲妥珠单抗治疗大约一年后就会出现耐药的情况，尤其是晚期转移性疾病患者，药物疗效大打折扣。就算联合化疗药物和帕妥珠单抗一起使用，还是有不少患者会耐药。这背后的原因，大家还没有完全搞清楚。目前的研究大多集中在药物与 HER2 的结合能力下降上，比如 HER2 受体从肿瘤细胞表面脱落等，但针对这些的新疗法效果也不太理想。

Neurodegenerative diseases, characterized by progressive neuronal loss and cognitive impairments, pose a significant global health challenge. This study explores the potential of nanotherapeutics as a ...

Delivering drugs to specific, hard-to-reach areas in the human body remains a challenge in drug development. Typically, drug ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three to six times each week. "It's been a ...

Laboratory of Precision Nanomedicine, Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv-Yafo 69978, Israel Department of Materials Sciences and Engineering, Tel Aviv ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. In this work, nanometric niosomes (158 ± 38 nm) presenting a narrow size distribution ...